# BPC-157: The Peptide That Gets Attached to Everything > BPC-157 — Research Peptide Fundamentals | The Peptide Train — BPC-157 among the Research Peptide Fundamentals research peptides: a large animal literature, three small human pilot studies, and no combination data at all. What the published record says, and where it stops. **01 — TISSUE REPAIR** A fifteen-amino-acid peptide with a deep rodent literature, a very small human one, and a habit of appearing as the second name in somebody else's blend. ## In plain English BPC-157 is a small synthetic peptide — fifteen amino acids long — copied from part of a protein found in human stomach fluid. Almost everything known about it comes from studies in rats. In those rodent studies it speeds up healing: stomach ulcers close faster, and a cut tendon recovers better than an untreated one. The leading explanation is that it encourages the growth of new blood vessels into damaged tissue, which is how repair gets its supply line. The human record is a different story. As of 2025, a published review counts three small pilot studies in people, and describes large rigorous trials as lacking [2]. That is why BPC-157 shows up constantly in discussion and almost never in a clinical guideline. It is not an approved medicine anywhere, and it is banned in competitive sport at all times. ## What it is BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — derived from a partial sequence of the human gastric juice protein known as body protection compound. Its molecular formula is C62H98N16O22. It circulates in the literature under several names, including pentadecapeptide BPC 157, PL 14736 and PL-10. Its standing is unambiguous and worth stating before anything else. It is not approved by the FDA for human use, and in 2023 the agency placed it in a category of substances identified as not eligible for pharmacy compounding under section 503A, pending further evaluation. It is sold by research suppliers for laboratory research use only, with no established human therapeutic indication. The World Anti-Doping Agency prohibits it in sport at all times under its category for non-approved substances. Those three facts travel with the molecule into every blend it is ever placed in — a point the [comparison page](/compare) returns to. ## How it works The mechanism most consistently linked to BPC-157's repair effects in animal models is angiogenesis: the formation of new blood vessels through damaged tissue. The best-characterised route runs through VEGFR2, the principal receptor for vascular endothelial growth factor. In work across chick chorioallantoic membrane, rat hindlimb ischaemia and human vascular endothelial cells, BPC157 up-regulated VEGFR2 expression and promoted its internalisation, with downstream activation of the VEGFR2-Akt-eNOS pathway; vessel density rose both in vivo and in vitro, blood-flow recovery in ischaemic muscle accelerated, and the effects were blocked when endocytosis was inhibited [4]. Several additional routes are reported. A review positioning the peptide as a brain-gut-axis mediator describes modulation of serotonergic and dopaminergic systems and implicates the Egr-1, NAB2, FAK-paxillin and JAK-2 pathways [7]. Sensitisation of the growth-hormone receptor in tendon fibroblasts and modulation of the nitric-oxide system are also described in the wider literature. The practical summary is that BPC-157 is characterised as a *cytoprotective* signal — one that makes tissue more able to survive insult and rebuild — rather than as a hormone with a single receptor and a single output. ## What the research actually shows **The human dataset is two studies deep and one of them has an n of two.** A first-in-human intravenous safety pilot gave BPC157 at up to 20 mg to two healthy adults, a 58-year-old man and a 68-year-old woman. It was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. That is a safety signal from a very small sample, not an efficacy result, and the study makes no claim to be one. **A 2025 narrative review is the honest summary of the field.** Reviewing BPC-157 for musculoskeletal healing, it concludes that despite broad preclinical support only three pilot studies have examined the peptide in humans, that rigorous large-scale trials are lacking, and that it is best regarded as investigational given both the regulatory picture and its non-regulated availability [2]. **Pharmacokinetics were formally characterised only recently, and in animals.** The first PK and ADME study, in rats and beagle dogs, found linear pharmacokinetics, an elimination half-life under 30 minutes, intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs, excretion by urine and bile, and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism [3]. **The foundational animal results are genuinely striking.** In Wistar rats, BPC 157 reduced gastric ulcer area and accelerated healing, with an ulcer-formation inhibition ratio of 45.7-65.6% at higher doses and intramuscular delivery outperforming intragastric [5]. In a fully transected rat Achilles tendon, it accelerated healing across biomechanical, functional, microscopic and macroscopic measures, improved collagen organisation, and stimulated tendocyte outgrowth in culture [6]. **And the caveat that reviewers keep raising.** A large share of the foundational literature was produced by a single research group and its collaborators, so independent replication is limited — a point newer reviewers flag explicitly [2]. Broad, consistent-looking findings that have not been widely confirmed by unrelated laboratories carry less weight than their consistency suggests. ## What users report, and what the cautions say What follows is anecdotal, not clinical evidence: reports gathered from peptide-user forums, clinic write-ups and published summaries of online discussion. No dose is described, no source is endorsed, and none of it was measured under controlled conditions. The reason most people in research-use communities try BPC-157 is musculoskeletal. Faster recovery from tendon, ligament and joint injuries is very commonly reported — stubborn problems such as tennis elbow, rotator-cuff strain and old sprains described as feeling more usable, often within the first one to three weeks. Reduced joint stiffness and easier painful movement are frequently reported alongside it. Improvements in digestive symptoms are also frequently reported, which people connect to the peptide's gastric origin: less bloating, cramping and urgency. Occasionally reported are faster closure of minor skin wounds, better sleep or mood, and a diffuse sense of reduced inflammation that commentators note is close to impossible to separate from placebo. On the adverse side, injection-site redness, stinging or a small bump is very commonly reported and described as fading within a day. Mild nausea or loose stools are frequently reported, more often with oral and sublingual products than with injections. Occasional reports include first-week fatigue, headache, brief dizziness on standing, and transient flushing or warmth that users link to the peptide's reported effect on blood-vessel tone. Palpitations are rarely reported, and commentators treat a persistent fast heartbeat, chest pain or marked blood-pressure change as a reason to stop and seek medical evaluation. The documented cautions are a different kind of statement, and several of them are structural rather than clinical. - **The human evidence is extremely thin.** Almost everything known comes from rodent work; a handful of small uncontrolled human reports exist, and large rigorous controlled trials do not [1][2]. Animal results are not proven benefits in people, and the real balance of benefit and risk in humans is unknown. - **Independent replication is limited**, for the single-group reason described above [2]. - **Not an approved drug, and unregulated products vary.** Because it moves through non-regulated channels, the identity, purity and actual content of any given product are unverified outside formal studies [2]. - **Strong pro-angiogenic activity raises a theoretical concern in cancer.** Tumours also depend on new blood vessels, so a strongly pro-angiogenic agent is a mechanism-based concern for anyone with an active or suspected malignancy [4]. This is reasoning from mechanism, not a finding from human studies. - **A possible interaction with serotonin-affecting medicines** has been raised on the basis of rodent work in which BPC-157 altered brain serotonin activity. The concern is theoretical and rests on animal data, with no human interaction study behind it. - **It promotes growth signalling and the long-term picture is unknown.** In cultured tendon cells it increased growth-hormone-receptor signalling. Any agent that nudges growth pathways raises a long-term question that no long-term human safety data exist to settle. - **Banned in competitive sport** at all times, which is an eligibility risk quite separate from any health effect. - **Untested in pregnancy, breastfeeding and children**, with no human data supporting use in those groups. ## Why it ends up coupled to something else BPC-157 is the most frequently bundled compound on this site, and the reason is that its claimed action is generic. *Repair* is not a receptor or an endpoint; it is a category. Anything that can be framed as restorative can be filed next to it without contradiction, which is exactly what makes the filing meaningless as evidence. The usual argument for pairing it with a growth-hormone-axis compound is that local repair signalling and systemic growth signalling ought to reinforce each other. That is a plausible sentence. It is not a study. No trial on this desk's source list gave BPC-157 with any other peptide and measured an outcome. There is also a pharmacokinetic problem that the pairing story tends to skip. BPC-157's elimination half-life in rats and dogs is under 30 minutes [3]. The DAC form of CJC-1295 has an estimated half-life of 5.8 to 8.1 days in healthy adults [11]. Two compounds whose exposure windows differ by roughly three orders of magnitude are not really acting *together* in any straightforward sense; they are two separate exposures on two separate clocks, and nothing published characterises what that looks like in combination. The honest position is the one the 2025 review takes about the single agent, only more so: investigational, incompletely characterised, and — in combination — entirely uncharacterised [2]. --- The Peptide Train follows four habitually bundled peptides back through their own published records and reports the exact point where the reporting has to stop — it sells nothing, prescribes nothing, and endorses no pairing to anyone.